Bullish indicating open at $55-$60, IPO prices at $37
CAMBRIDGE, Mass. - Vyome Therapeutics, Inc. announced its new Board of Directors will take control of ReShape Lifesciences (NASDAQ:RSLS) on Friday, August 15, 2025, when the company will be renamed Vyome Holdings, Inc. and begin trading under the ticker symbol HIND. The announcement comes as RSLS trades near its 52-week low of $1.87, with a current market capitalization of $4.56 million. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value metrics.
The incoming board consists of six members with ties to both the United States and India, including four Massachusetts Institute of Technology (MIT) alumni. None of ReShape’s current board members or management team will remain with the company after the transition. The leadership change comes as the company faces financial challenges, with InvestingPro data showing negative EBITDA of -$6.28 million and annual revenue of $7.17 million.
"We are offering RSLS shareholders significant potential value, and no member of the ReShape board or its management team has been invited to join Vyome Holdings," said Krishna Gupta, who will serve as Chairman of Vyome Holdings.
The new board includes Gupta, founder Shiladitya Sengupta, co-founder and CEO Venkat Nelabhotla, and three shareholder representatives: Mohanjit Jolly, John Tincoff, and Stash Pomichter.
According to the press release, Vyome Therapeutics is a clinical-stage healthcare company focusing on immuno-inflammatory and rare diseases. The company describes itself as building a healthcare platform spanning the "US-India innovation corridor."
The announcement comes as part of Vyome’s previously disclosed reverse merger with ReShape Lifesciences. Upon completion of the transaction, the company states it will have "no debt, no toxic structure" and all major shareholders will be subject to lock-up agreements.
The merger remains subject to customary closing conditions, including approval by ReShape stockholders and continued listing approval from Nasdaq. With the company’s next earnings report due on August 19, 2025, investors can access comprehensive analysis and 14 additional key insights through InvestingPro’s detailed research reports, which provide deep-dive analysis of 1,400+ US stocks.
In other recent news, ReShape Lifesciences Inc. announced a strategic workforce reduction aimed at saving over $750,000 annually, which accounts for approximately 23% of its wage expenses. The company has also regained compliance with Nasdaq’s stockholders’ equity requirement, thereby avoiding potential delisting from the exchange. Additionally, ReShape Lifesciences has entered into a promissory note agreement with Vyome Therapeutics, providing a $200,000 loan under the terms of a pending merger agreement. In the realm of intellectual property, the U.S. Patent and Trademark Office will issue a new patent to ReShape Lifesciences for its intragastric balloon system, set to be granted on July 8, 2025. Furthermore, the company has been awarded an Australian patent for its Diabetes Neuromodulation technology, which will provide protection until April 2039. These developments reflect ReShape Lifesciences’ ongoing efforts in financial management, strategic partnerships, and innovation in medical technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.